Bimekizumab (anti-IL17A&IL-17F) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab (anti-IL17A&IL-17F) blocks the inflammation-driven osteogenic differentiation.Purity≥95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
Specification: ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/AB182793-SCI_31c472c3cc34d4e88d8d9fe7b566d353.pdf
- UPC:
- 51201569
- Condition:
- New
- Availability:
- 4-8 weeks
- Weight:
- 0.07 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- Ab182793-10mg
- CAS:
- 1418205-77-2
- Product Size:
- 10mg